BEONE MEDICINES LTD-ADR (ONC) Fundamental Analysis & Valuation

NASDAQ:ONC • US07725L1026

Current stock price

312.31 USD
-5.76 (-1.81%)
At close:
312.31 USD
0 (0%)
After Hours:

This ONC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ONC Profitability Analysis

1.1 Basic Checks

  • In the past year ONC was profitable.
  • ONC had a positive operating cash flow in the past year.
  • ONC had negative earnings in each of the past 5 years.
  • In the past 5 years ONC always reported negative operating cash flow.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2B -4B -6B -8B -10B

1.2 Ratios

  • ONC's Return On Assets of -0.28% is amongst the best of the industry. ONC outperforms 87.40% of its industry peers.
  • With an excellent Return On Equity value of -0.52%, ONC belongs to the best of the industry, outperforming 89.34% of the companies in the same industry.
  • ONC's Return On Invested Capital of 1.88% is amongst the best of the industry. ONC outperforms 88.57% of its industry peers.
Industry RankSector Rank
ROA -0.28%
ROE -0.52%
ROIC 1.88%
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • ONC has a better Operating Margin (2.86%) than 88.37% of its industry peers.
  • ONC has a Gross Margin of 85.99%. This is amongst the best in the industry. ONC outperforms 87.60% of its industry peers.
  • ONC's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.86%
PM (TTM) N/A
GM 85.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ONC Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ONC is destroying value.
  • Compared to 1 year ago, ONC has more shares outstanding
  • ONC has more shares outstanding than it did 5 years ago.
  • ONC has a worse debt/assets ratio than last year.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.2 Solvency

  • ONC has an Altman-Z score of 5.49. This indicates that ONC is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ONC (5.49) is better than 73.26% of its industry peers.
  • ONC has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as ONC would need 2.51 years to pay back of all of its debts.
  • ONC has a Debt to FCF ratio of 2.51. This is amongst the best in the industry. ONC outperforms 93.41% of its industry peers.
  • A Debt/Equity ratio of 0.23 indicates that ONC is not too dependend on debt financing.
  • ONC has a worse Debt to Equity ratio (0.23) than 67.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 2.51
Altman-Z 5.49
ROIC/WACC0.39
WACC4.79%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B

2.3 Liquidity

  • ONC has a Current Ratio of 2.40. This indicates that ONC is financially healthy and has no problem in meeting its short term obligations.
  • ONC has a Current ratio of 2.40. This is in the lower half of the industry: ONC underperforms 72.48% of its industry peers.
  • A Quick Ratio of 2.17 indicates that ONC has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.17, ONC is doing worse than 73.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.17
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ONC Growth Analysis

3.1 Past

  • ONC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 381.78%, which is quite impressive.
  • Looking at the last year, ONC shows a very strong growth in Revenue. The Revenue has grown by 56.19%.
  • Measured over the past years, ONC shows a very strong growth in Revenue. The Revenue has been growing by 55.91% on average per year.
EPS 1Y (TTM)381.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.75%
Revenue 1Y (TTM)56.19%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%34.26%

3.2 Future

  • ONC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 96.91% yearly.
  • Based on estimates for the next years, ONC will show a quite strong growth in Revenue. The Revenue will grow by 18.35% on average per year.
EPS Next Y145.53%
EPS Next 2Y70.5%
EPS Next 3Y49.39%
EPS Next 5Y96.91%
Revenue Next Year41.11%
Revenue Next 2Y29.88%
Revenue Next 3Y25%
Revenue Next 5Y18.35%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20B 40B 60B 80B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1K 2K

More info and screens

Find the best growth stocksShow best growing peers

6

4. ONC Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 15.02, ONC is valued correctly.
  • Compared to the rest of the industry, the Price/Earnings ratio of ONC indicates a rather cheap valuation: ONC is cheaper than 95.93% of the companies listed in the same industry.
  • ONC's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.71.
  • A Price/Forward Earnings ratio of 46.67 indicates a quite expensive valuation of ONC.
  • Based on the Price/Forward Earnings ratio, ONC is valued cheaply inside the industry as 90.12% of the companies are valued more expensively.
  • ONC is valuated rather expensively when we compare the Price/Forward Earnings ratio to 38.09, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.02
Fwd PE 46.67
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, ONC is valued cheaper than 92.05% of the companies in the same industry.
Industry RankSector Rank
P/FCF 71.21
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ONC's earnings are expected to grow with 49.39% in the coming years.
PEG (NY)0.1
PEG (5Y)N/A
EPS Next 2Y70.5%
EPS Next 3Y49.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ONC Dividend Analysis

5.1 Amount

  • ONC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ONC Fundamentals: All Metrics, Ratios and Statistics

BEONE MEDICINES LTD-ADR

NASDAQ:ONC (4/21/2026, 8:04:52 PM)

After market: 312.31 0 (0%)

312.31

-5.76 (-1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-12
Inst Owners41.09%
Inst Owner Change-0.02%
Ins OwnersN/A
Ins Owner Change7.12%
Market Cap34.67B
Revenue(TTM)27.21B
Net Income(TTM)-153.00M
Analysts82.67
Price Target468.82 (50.11%)
Short Float %14.98%
Short Ratio4.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.56
Dividend Growth(5Y)N/A
DP-360.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)590.84%
Min EPS beat(2)-5.45%
Max EPS beat(2)1187.13%
EPS beat(4)3
Avg EPS beat(4)1523.03%
Min EPS beat(4)-5.45%
Max EPS beat(4)3109.85%
EPS beat(8)3
Avg EPS beat(8)516.07%
EPS beat(12)4
Avg EPS beat(12)343.82%
EPS beat(16)5
Avg EPS beat(16)253.79%
Revenue beat(2)1
Avg Revenue beat(2)2.46%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)6.29%
Revenue beat(4)2
Avg Revenue beat(4)2.29%
Min Revenue beat(4)-1.36%
Max Revenue beat(4)6.29%
Revenue beat(8)6
Avg Revenue beat(8)8.35%
Revenue beat(12)10
Avg Revenue beat(12)12.39%
Revenue beat(16)13
Avg Revenue beat(16)10.75%
PT rev (1m)28.4%
PT rev (3m)34.83%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)-14.15%
EPS NY rev (1m)-1.03%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-0.16%
Valuation
Industry RankSector Rank
PE 15.02
Fwd PE 46.67
P/S 6.63
P/FCF 71.21
P/OCF 48.59
P/B 8.06
P/tB 8.41
EV/EBITDA N/A
EPS(TTM)20.79
EY6.66%
EPS(NY)6.69
Fwd EY2.14%
FCF(TTM)4.39
FCFY1.4%
OCF(TTM)6.43
OCFY2.06%
SpS47.14
BVpS38.76
TBVpS37.13
PEG (NY)0.1
PEG (5Y)N/A
Graham Number134.658 (-56.88%)
Profitability
Industry RankSector Rank
ROA -0.28%
ROE -0.52%
ROCE 2.73%
ROIC 1.88%
ROICexc 5.89%
ROICexgc 6.47%
OM 2.86%
PM (TTM) N/A
GM 85.99%
FCFM 9.3%
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 2.51
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 4.33%
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.17
Altman-Z 5.49
F-Score7
WACC4.79%
ROIC/WACC0.39
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)381.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.75%
EPS Next Y145.53%
EPS Next 2Y70.5%
EPS Next 3Y49.39%
EPS Next 5Y96.91%
Revenue 1Y (TTM)56.19%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%34.26%
Revenue Next Year41.11%
Revenue Next 2Y29.88%
Revenue Next 3Y25%
Revenue Next 5Y18.35%
EBIT growth 1Y115.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year208.07%
EBIT Next 3Y66%
EBIT Next 5Y54.47%
FCF growth 1Y131.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y172.14%
OCF growth 3YN/A
OCF growth 5YN/A

BEONE MEDICINES LTD-ADR / ONC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BEONE MEDICINES LTD-ADR (ONC) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ONC.


What is the valuation status for ONC stock?

ChartMill assigns a valuation rating of 6 / 10 to BEONE MEDICINES LTD-ADR (ONC). This can be considered as Fairly Valued.


Can you provide the profitability details for BEONE MEDICINES LTD-ADR?

BEONE MEDICINES LTD-ADR (ONC) has a profitability rating of 5 / 10.


What is the valuation of BEONE MEDICINES LTD-ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BEONE MEDICINES LTD-ADR (ONC) is 15.02 and the Price/Book (PB) ratio is 8.06.


What is the financial health of BEONE MEDICINES LTD-ADR (ONC) stock?

The financial health rating of BEONE MEDICINES LTD-ADR (ONC) is 5 / 10.